Answers are grounded in this paper and cite their sources.
Trial reveals a nanobooster restores antibiotic susceptibility in Pseudomonas aeruginosa, suggesting new treatment paths.
Mucoid Pseudomonas aeruginosa (m.PAE) presents a major clinical challenge due to its high resistance to ceftazidime (CAZ), a cornerstone antibiotic. This resistance is orchestrated through three barriers, including the formation...
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: